Skip to content

Study · Not a test of the peptide alone · 2009

1 result

MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family.

Chan LF, Webb TR, Chung TT, Meimaridou E, Cooray SN, Guasti L, Guasti L, Chapple JP, Egertová M, Elphick MR, Cheetham ME, Metherell LA, Clark AJ

Proceedings of the National Academy of Sciences of the United States of America27 Mar 2009Cited by 199 (Europe PMC)

PMID19329486 (opens in a new tab)PMCIDPMC2661846 (opens in a new tab)DOI10.1073/pnas.0809918106 (opens in a new tab)PepBankPUB-19329486
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Mechanism

    In cells, MRAP and MRAP2 reduced the responsiveness of MC1R, MC3R, MC4R and MC5R to NDP-MSH.

    In plain wordsIn cells, the proteins MRAP and MRAP2 made four melanocortin receptors respond less to NDP-MSH.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseMCR responsiveness to NDP-MSH with MRAP and MRAP2
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    In contrast, MRAP and MRAP2 can reduce MC1R, MC3R, MC4R, and MC5R responsiveness to [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone (NDP-MSH).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.